BioNotebook: Agios, Kite raise cash on ASH buzz; plus 5 other public offerings
This article was originally published in Scrip
Executive Summary
The 56th American Society of Hematology (ASH) Annual Meeting and Exposition from 6 to 9 December in San Francisco lifted the stock values of several companies with promising data for blood cancers, including Agios Pharmaceuticals and Kite Pharma, which are taking advantage of the buzz their lead programs generated at the ASH conference to raise a combined $408m in public offerings.